The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):195-200. doi: 10.1097/QAI.0b013e3182895565.

Abstract

Objective: To estimate the cost-effectiveness of HIV screening strategies for the prevention of perinatal transmission in Uganda, a resource-limited country with high HIV prevalence and incidence.

Study design: We designed a decision analytic model from a health care system perspective to assess the vertical transmission rates and cost-effectiveness of 4 different HIV screening strategies in pregnancy: (1) rapid HIV antibody (Ab) test at initial visit (current standard of care), (2) strategy 1 + HIV RNA at initial visit (adds detection of acute HIV), (3) strategy 1 + repeat HIV Ab at delivery (adds detection of incident HIV), and (4) strategy 3 + HIV RNA at delivery (adds detection of acute HIV at delivery). Model estimates were derived from the literature and local sources, and life years saved were discounted at a rate of 3% per year. Based on World Health Organization guidelines, we defined our cost-effectiveness threshold as ≤3 times the gross domestic product per capita, which for Uganda was US$3300 in 2008.

Results: Using base case estimates of 10% HIV prevalence among women entering prenatal care and 3% incidence during pregnancy, strategy 3 was incrementally the cost-effective option that led to the greatest total life years.

Conclusions: Repeat rapid HIV Ab testing at the time of labor is a cost-effective strategy even in a resource-limited setting such as Uganda.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Cost-Benefit Analysis
  • Decision Support Techniques
  • Female
  • HIV Antibodies / blood
  • HIV Antibodies / economics
  • HIV Infections / diagnosis*
  • HIV Infections / economics
  • HIV Infections / prevention & control
  • HIV Infections / transmission*
  • HIV-1 / genetics
  • HIV-1 / immunology
  • Health Resources / economics
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Mass Screening / economics*
  • Pregnancy
  • Pregnancy Complications, Infectious / diagnosis
  • Pregnancy Complications, Infectious / economics
  • Prenatal Care / economics*
  • Quality-Adjusted Life Years
  • RNA, Viral / analysis
  • Uganda

Substances

  • HIV Antibodies
  • RNA, Viral